A pdf copy of the resolution is attached to this page.
THE FIFTY-SECOND WORLD HEALTH ASSEMBLY
WHA52.19
Agenda Item 13
May 24, 1999
The Fifty-second World Health Assembly,
Recalling resolution WHA39.27, WHA41.16, WHA43.20, WHA45.27, WHA47.12, WHA47.13, WHA47.16, WHA47.17, and WHA49.14;
Having considered the report of the Director-General on the revised drug strategy[1];
CONFIDENTIAL RELEASED IN FULL
CONFIDENTIAL PTQ1906
PAGE 01 GENEVA 03470 01 OF 09 271621Z ACTION 10-00
425261 271705Z /38 O 271615Z MAY 98
FM USMISSION GENEVA
TO SECSTATE WASHDC IMMEDIATE 6208 INFO IO COLLECTIVE AMEMBASSY LONDON
AMEMBASSY BRASILIA
AMEMBASSY BUENOS AIRES AMEMBASSY PRETORIA AMEMBASSY HARARE
AMEMBASSY LILONGWE AMEMBASSY LUSAKA
AMEMBASSY WINDHOEK AMEMBASSY BERN
AMEMBASSY CANBERRA
AMEMBASSY STOCKHOLM AMEMBASSY TOKYO AMEMBASSY OSLO
AMEMBASSY BRUSSELS AMEMBASSY BONN
AMEMBASSY OTTAWA AMEMBASSY CAIRO CDC ATLANTA
Draft
This is work in progress, and is part of a larger project on timelines. This particular timeline is unfinished, and may contain errors.
On Tuesday, August 17, 2010, USTR organized a lunch between ACTA negotiators and civil society NGOs. There was not much notice. We received our invite to the lunch last Thursday. Representatives from KEI, Public Citizen, Oxfam, Public Knowledge and the American University program on intellectual property attended the event.
Beginning in 1985, the United States government (USG) diplomatic and trade officials have engaged in wide ranging activities aimed at changing global norms for the protection of intellectual property rights, with a particular emphasis on the IPR protections for pharmaceutical products.
This note reports on U.S. Department of State cables sent in 1986 and 1987, that discussed the U.S. government efforts to change policies in Brazil on the intellectual property protection for pharmaceutical products. The cables have been obtained by KEI with a FOIA request.
Prices for Abbott’s Norvir (generic name Ritonavir) as a Standalone Product in 2010 KEI Research Note 2010:4 August 12, 2010 Anne Mira Guha Prices for Abbott’s Norvir (generic name Ritonavir) as a Standalone Product in 2010 1. Introduction Ritonavir is… Continue Reading
From the FDA page on the Orphan Drug Tax Credit. Incentives TAX CREDIT (See Footnote 1 below) FOR TESTING EXPENSES FOR DRUGS FOR RARE DISEASES OR CONDITIONS Introduction Section 45C of the Internal Revenue Code of 1954 allows a credit… Continue Reading
From the FDA page on the Orphan Drug Tax Credit.
IncentivesTAX CREDIT
(See Footnote 1 below)
FOR TESTING EXPENSES FOR
DRUGS FOR RARE DISEASES OR CONDITIONSIntroduction
Section 45C of the Internal Revenue Code of 1954 allows a credit against tax, up to 50 percent of certain clinical testing expenses related to the use of a drug for a rare disease or condition after it is designated as an orphan drug.Notes on the 2004 to 2009 United States Food and Drug Administration Approval of New Molecular Entities (NMEs)
(Cite as Molly Redfield Ward, Notes on the 2004 to 2009 United States Food and Drug Administration Approval of New Molecular Entities (NMEs), KEI Research Note 2010:3) A PDF version of this document is available here. Notes on the 2004… Continue Reading
Notes and data points for prices of orphan products
February 22, 2010., Matthew Herper, “The World’s Most Expensive Drugs,” Forbes. Genzyme’s web page on the cost of treatment. Some data points on Fabrazyme prices. 2004 prices for Replagal 2001 prices for Cerezyme. Myozyme/Lumizyme A 2007 Canadian analysis of (50… Continue Reading